Intentional self-harm by jumping or lying before moving object

VWXY20_INTENTI_SELF_H_JUMPI_LYING_MOVING_OBJECT

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519870
1. Apply sex-specific rule None	519870
2. Check conditions None	519870
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — X81 Cause of death: ICD-10 — X81 2 out of 7 registries used, show all original rules.	69
4. Check minimum number of events None	69
5. Include endpoints None	69
6. Filter based on genotype QC (FinnGen only)	67

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF4
Parent code in ICD-10: X[6-7]|X8[0-4]

NAME	VWXY20_INTENTI_SELF_H_JUMPI_LYING_MOVING_OBJECT
CONTROL_EXCLUDE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	X81
HD_ICD_9
HD_ICD_8
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	X81
COD_ICD_9
COD_ICD_8
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Intentional self-harm by jumping or lying before moving object based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	67	27	40
Unadjusted period prevalence (%)	0.01	0.01	0.02
Median age at first event (years)	36.65	37.61	36.01

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
69: Matched controls
690

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

X81

ICD-10 Finland

Intentional self-harm by jumping or lying before moving object

+∞

99.1

112

Kela drug reimbursment

Severe psychotic and other severe mental disorders

39.7

54.2

N05AH03

ATC

olanzapine; systemic

23.5

38.1

N05AH04

ATC

quetiapine; oral

15.6

30.5

F32.9

ICD-10 Finland

Depressive episode, unspecified

12.4

23.9

X69

ICD-10 Finland

Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances

32.7

16.3

N05AX08

ATC

risperidone; systemic

16.3

16.1

T36

ICD-10 Finland

Poisoning by systemic antibiotics

24.1

15.6

N05AX12

ATC

aripiprazole; systemic

15.1

13.6

F29

ICD-10 Finland

Unspecified nonorganic psychosis

15.1

13.6

F32.3

ICD-10 Finland

Severe depressive episode with psychotic symptoms

86.3

13.1

F99

ICD-10 Finland

Mental disorder, not otherwise specified

47.0

12.8

N03AG01

ATC

valproic acid; systemic, rectal

14.5

12.4

Z00.4

ICD-10 Finland

General psychiatric examination, not elsewhere classified

7.2

12.3

N06AB04

ATC

citalopram; systemic

6.2

11.6

N05AH02

ATC

clozapine; systemic

22.6

11.4

N06AB03

ATC

fluoxetine; oral

6.7

10.0

N05CF01

ATC

zopiclone; oral

5.0

9.8

102

GD1UA

NOMESCO Finland

Thorax X-ray examination outside radiological department

6.0

9.0

F10.0

ICD-10 Finland

Mental and behavioural disorders due to use of alcohol, Acute intoxication

57.6

8.9

F60.31

ICD-10 Finland

Emotionally unstable personality disorder, borderline condition

102.0

8.6

F20.9

ICD-10 Finland

Schizophrenia, unspecified

17.4

8.6

R99

ICD-10 Finland

Other ill-defined and unspecified causes of mortality

+∞

8.5

N06AB06

ATC

sertraline; oral

5.1

8.3

F33.2

ICD-10 Finland

Recurrent depressive disorder, current episode severe without psychotic symptoms

8.0

8.3

A98

ICPC

Health maint/preventive medicine

0.2

8.3

646

OAB43, ,

SPAT

0.1

8.0

270

F10.09

ICD-10 Finland

Alcohol intoxication UNS

18.3

7.5

N05BA04

ATC

oxazepam; oral

4.1

7.3

F10.29

ICD-10 Finland

Addiction caused by alcohol UNS

16.0

7.2

N05BA06

ATC

lorazepam; systemic, sublingual

11.1

7.2

F10.1

ICD-10 Finland

Mental and behavioural disorders due to use of alcohol, Harmful use

7.7

7.0

F20.00

ICD-10 Finland

Paranoid schizophrenia continuous

19.1

7.0

N05AA02

ATC

levomepromazine; systemic

11.8

6.8

ZY000

NOMESCO Finland

Hospital inpatient

16.4

6.6

F31.20

ICD-10 Finland

Bipolar disorder, manic episode with mood-congruent psychotic symptoms

76.6

6.5

F33.30

ICD-10 Finland

Recurrent depression, severe episode without somatic syndrome

76.6

6.5

F31.4

ICD-10 Finland

Bipolar affective disorder, current episode severe depression without psychotic symptoms

76.6

6.5

F33.9

ICD-10 Finland

Recurrent depressive disorder, unspecified

9.1

6.5

N05AB03

ATC

perphenazine; systemic, rectal

20.4

6.4

F60.9

ICD-10 Finland

Personality disorder, unspecified

29.7

6.4

F31.9

ICD-10 Finland

Bipolar affective disorder, unspecified

14.3

6.3

N03AX09

ATC

lamotrigine; oral

8.6

6.3

IAA01

NOMESCO Finland

Assessment of need for psychiatric treatment

9.4

6.1

ZXE02

NOMESCO Finland

Procedure duration 10 to 19 minutes

9.4

6.1

N05BA01

ATC

diazepam; systemic, rectal

4.8

6.1

NA1AD

NOMESCO Finland

Cervical spine CT examination

10.6

6.0

TimeCodeWAS

↥

TODO / Current known limitations:

Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
Legend / how to read the glyphs.
Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
Download CSV.
No filters and sorters.
Limited amount of endpoints (~400) having TimeCodeWAS data.
Cross-links to Risteys lab test pages for lab test codes.

OMOP concept

ln(OR)

%cases with code / %controls with code

2×2 table

Psychiatry
26 [38004469]

2.7e+00

2.9e+00

2.8e+00

—

cases:57.97%

controls:8.84%

cases:55.07%

controls:6.09%

cases:27.54%

controls:2.17%

—

629

648

675

—

olanzapine; oral, parenteral
N05AH03 [21604543]

3.1e+00

3.4e+00

—

cases:26.09%

controls:1.59%

cases:21.74%

controls:0.87%

—

679

684

—

Unspecified nonorganic psychosis
F29 [45533099]

2.7e+00

3.0e+00

—

1.0e+50

—

cases:20.29%

controls:1.74%

cases:13.04%

controls:0.72%

—

cases:7.25%

controls:0.00%

—

678

685

—

690

—

Inpatient Hospital
21 [8717]

1.0e+00

1.9e+00

2.4e+00

1.0e+50

—

cases:52.17%

controls:28.55%

cases:36.23%

controls:7.54%

cases:11.59%

controls:1.16%

cases:23.19%

controls:0.00%

—

197

493

638

682

690

—

clozapine; oral, parenteral
N05AH02 [21604542]

2.5e+00

2.7e+00

—

cases:13.04%

controls:1.16%

cases:10.14%

controls:0.72%

—

682

685

—

quetiapine; oral
N05AH04 [21604544]

2.7e+00

2.3e+00

2.2e+00

—

cases:34.78%

controls:3.33%

cases:21.74%

controls:2.61%

cases:7.25%

controls:0.87%

—

667

672

684

—

aripiprazole; oral, parenteral
N05AX12 [21604562]

2.2e+00

2.8e+00

—

cases:14.49%

controls:1.88%

cases:13.04%

controls:0.87%

—

677

684

—

valproic acid; oral, parenteral, rectal
N03AG01 [21604422]

2.5e+00

2.4e+00

—

cases:13.04%

controls:1.16%

cases:7.25%

controls:0.72%

—

682

685

—

sertraline; oral
N06AB06 [21604714]

2.6e+00

2.1e+00

—

cases:17.39%

controls:1.59%

cases:8.70%

controls:1.16%

—

679

682

—

Dedicated profession-specific psychiatric intervention, individual
IEY05 [2001304224]

2.2e+00

2.4e+00

—

cases:8.70%

controls:1.01%

cases:8.70%

controls:0.87%

—

683

684

—

Participation in compiling a psychiatric treatment plan
ICZ03 [2001304119]

2.1e+00

2.2e+00

—

cases:8.70%

controls:1.16%

cases:8.70%

controls:1.01%

—

682

683

—

oxazepam; oral
N05BA04 [21604569]

2.0e+00

2.1e+00

—

cases:23.19%

controls:3.91%

cases:20.29%

controls:2.90%

—

663

670

—

Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]

1.7e+00

2.5e+00

—

cases:18.84%

controls:4.20%

cases:21.74%

controls:2.32%

—

661

674

—

Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]

1.2e+00

1.0e+00

1.7e+00

—

cases:50.72%

controls:24.06%

cases:33.33%

controls:15.51%

cases:11.59%

controls:2.32%

—

166

524

107

583

674

—

Case Management Agency
251B00000X [38004193]

3.1e-01

4.4e-01

9.6e-01

2.7e+00

—

cases:71.01%

controls:64.20%

cases:63.77%

controls:53.19%

cases:37.68%

controls:18.84%

cases:18.84%

controls:1.59%

—

443

247

367

323

130

560

679

—

mirtazapine; oral
N06AX11 [21604740]

1.6e+00

1.9e+00

—

cases:21.74%

controls:5.07%

cases:15.94%

controls:2.75%

—

655

671

—

lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]

—

3.0e+00

—

cases:13.04%

controls:0.72%

—

685

—

Norclozapine [Moles/volume] in Serum or Plasma
14851-0 [3008832]

2.9e+00

—

cases:11.59%

controls:0.72%

—

685

—

cloZAPine [Moles/volume] in Serum or Plasma
14656-3 [3000081]

2.9e+00

—

cases:11.59%

controls:0.72%

—

685

—

risperidone; oral, parenteral
N05AX08 [21604559]

2.9e+00

—

cases:17.39%

controls:1.16%

—

682

—

Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]

1.2e+00

1.5e+00

—

cases:36.23%

controls:14.06%

cases:30.43%

controls:8.99%

—

593

628

—

Hospital inpatient
ZY000 [2001311598]

2.7e+00

—

cases:10.14%

controls:0.72%

—

685

—

Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]

7.1e-01

1.1e+00

1.6e+00

—

cases:39.13%

controls:24.06%

cases:37.68%

controls:16.67%

cases:13.04%

controls:2.90%

—

166

524

115

575

670

—

Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]

1.3e+00

1.4e+00

1.6e+00

—

cases:31.88%

controls:11.16%

cases:23.19%

controls:6.96%

cases:7.25%

controls:1.59%

—

613

642

679

—

General psychiatric examination, not elsewhere classified
Z00.4 [45605094]

2.7e+00

—

cases:11.59%

controls:0.87%

—

684

—

Severe psychotic and other severe mental disorders
112 [2001600112]

2.7e+00

—

cases:23.19%

controls:2.03%

—

676

—

Emergency Medicine
93 [38004510]

9.9e-01

1.6e+00

—

1.0e+50

—

cases:27.54%

controls:12.32%

cases:21.74%

controls:5.22%

—

cases:14.49%

controls:0.00%

—

605

654

—

690

—

Assessment of need for psychiatric treatment
IAA01 [2001304011]

—

2.6e+00

—

cases:8.70%

controls:0.72%

—

685

—

Methadone [Presence] in Urine by Screen method
19550-3 [3028707]

2.5e+00

—

cases:14.49%

controls:1.30%

—

681

—

Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]

1.1e+00

1.3e+00

—

cases:44.93%

controls:21.16%

cases:31.88%

controls:11.01%

—

146

544

614

—

Procedure duration 10 to 19 minutes
ZXE02 [2001311396]

2.4e+00

—

cases:11.59%

controls:1.16%

—

682

—

Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]

1.2e+00

—

cases:39.13%

controls:16.81%

cases:26.09%

controls:9.28%

—

116

574

626

—

Recurrent depressive disorder, current episode severe without psychotic symptoms
F33.2 [45547705]

2.4e+00

—

cases:10.14%

controls:1.01%

—

683

—

Internal Medicine
11 [38004456]

1.1e+00

1.3e+00

2.2e+00

—

cases:34.78%

controls:15.22%

cases:20.29%

controls:6.52%

cases:7.25%

controls:0.87%

—

105

585

645

684

—

Psychiatric treatment plan, standard
ICB01 [2001304098]

—

2.4e+00

—

cases:7.25%

controls:0.72%

—

685

—

Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]

1.1e+00

1.3e+00

—

cases:44.93%

controls:21.74%

cases:33.33%

controls:12.46%

—

150

540

604

—

Emergency Room Visit
ER [9203]

9.3e-01

1.4e+00

—

cases:56.52%

controls:33.91%

cases:34.78%

controls:11.59%

—

234

456

610

—

Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]

1.3e+00

1.1e+00

—

cases:37.68%

controls:14.64%

cases:23.19%

controls:9.42%

—

101

589

625

—

temazepam; oral
N05CD07 [21604642]

2.2e+00

—

cases:20.29%

controls:2.61%

—

672

—

Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]

—

2.2e+00

—

cases:8.70%

controls:1.01%

—

683

—

Drugs identified in Urine by Screen method Nominal
12286-1 [3011288]

2.2e+00

—

cases:13.04%

controls:1.59%

—

679

—

Depressive episode, unspecified
F32.9 [45571760]

2.2e+00

—

1.0e+50

—

cases:15.94%

controls:2.03%

—

cases:7.25%

controls:0.00%

—

676

—

690

—

Procedure duration 90 to 119 minutes
ZXE13 [2001311404]

2.2e+00

—

cases:11.59%

controls:1.45%

—

680

—

Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]

1.2e+00

9.9e-01

1.6e+00

—

cases:50.72%

controls:24.35%

cases:33.33%

controls:15.65%

cases:10.14%

controls:2.17%

—

168

522

108

582

675

—

Procedure duration 50 to 59 minutes
ZXE06 [2001311400]

2.1e+00

—

cases:10.14%

controls:1.30%

—

681

—

Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]

2.1e+00

—

cases:13.04%

controls:1.88%

—

677

—

diazepam; oral, parenteral, rectal
N05BA01 [21604566]

2.0e+00

—

cases:10.14%

controls:1.45%

—

680

—

Buprenorphine [Presence] in Urine by Screen method
93494-3 [1001926]

2.0e+00

—

cases:14.49%

controls:2.17%

—

675

—

zopiclone; oral
N05CF01 [21604654]

2.0e+00

1.8e+00

—

cases:24.64%

controls:4.20%

cases:10.14%

controls:1.88%

—

661

677

—

citalopram; oral, parenteral
N06AB04 [21604712]

2.0e+00

—

cases:11.59%

controls:1.74%

—

678

—

fluoxetine; oral
N06AB03 [21604711]

1.9e+00

2.2e+00

—

cases:10.14%

controls:1.59%

cases:7.25%

controls:0.87%

—

679

684

—

Cocaine [Presence] in Urine
3397-7 [3016879]

1.9e+00

—

cases:14.49%

controls:2.46%

—

673

—

Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]

1.9e+00

1.6e+00

—

cases:21.74%

controls:4.06%

cases:10.14%

controls:2.17%

—

662

675

—

Anxiety disorder, unspecified
F41.9 [45542849]

1.8e+00

1.6e+00

—

cases:10.14%

controls:1.74%

cases:7.25%

controls:1.59%

—

678

679

—

Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]

8.7e-01

9.1e-01

8.2e-01

—

cases:49.28%

controls:28.84%

cases:36.23%

controls:18.55%

cases:7.25%

controls:3.33%

—

199

491

128

562

667

—

Benzodiazepines [Presence] in Urine
3390-2 [3000764]

1.8e+00

—

cases:14.49%

controls:2.75%

—

671

—

Amphetamines [Presence] in Urine
3349-8 [3027944]

1.8e+00

—

cases:14.49%

controls:2.75%

—

671

—

Opiates [Presence] in Urine
3879-4 [3027008]

1.8e+00

—

cases:14.49%

controls:2.75%

—

671

—

Cannabinoids [Presence] in Urine
3427-2 [3028300]

1.8e+00

—

cases:14.49%

controls:2.75%

—

671

—

Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]

1.7e+00

—

cases:13.04%

controls:2.61%

—

672

—

pH of Serum or Plasma
2753-2 [3018418]

1.7e+00

1.5e+00

—

cases:14.49%

controls:3.04%

cases:8.70%

controls:2.03%

—

669

676

—

Outpatient Hospital
22 [8756]

6.8e-01

1.7e+00

—

1.0e+50

—

cases:33.33%

controls:20.14%

cases:17.39%

controls:3.77%

—

cases:10.14%

controls:0.00%

—

139

551

664

—

690

—

Hospital outpatient
ZY010 [2001311599]

1.6e+00

—

cases:11.59%

controls:2.46%

—

673

—

Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]

1.6e+00

—

cases:17.39%

controls:4.06%

—

662

—

Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]

1.6e+00

1.3e+00

—

cases:20.29%

controls:4.93%

cases:8.70%

controls:2.46%

—

656

673

—

Office Visit
OMOP4822458 [581477]

1.5e+00

9.1e-01

—

cases:24.64%

controls:6.52%

cases:7.25%

controls:3.04%

—

645

669

—

Hemoglobin [Mass/volume] in Blood
718-7 [3000963]

6.5e-01

6.8e-01

1.5e+00

—

cases:52.17%

controls:36.23%

cases:43.48%

controls:27.97%

cases:17.39%

controls:4.49%

—

250

440

193

497

659

—

Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]

6.5e-01

6.8e-01

1.5e+00

—

cases:52.17%

controls:36.23%

cases:43.48%

controls:27.97%

cases:17.39%

controls:4.49%

—

250

440

193

497

659

—

MCH [Entitic mass]
28539-5 [3035941]

6.5e-01

6.9e-01

1.5e+00

—

cases:52.17%

controls:36.23%

cases:43.48%

controls:27.83%

cases:17.39%

controls:4.49%

—

250

440

192

498

659

—

MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]

6.5e-01

6.9e-01

1.5e+00

—

cases:52.17%

controls:36.23%

cases:43.48%

controls:27.83%

cases:17.39%

controls:4.49%

—

250

440

192

498

659

—

Erythrocytes [#/volume] in Blood
26453-1 [3026361]

6.5e-01

6.8e-01

1.5e+00

—

cases:52.17%

controls:36.23%

cases:43.48%

controls:27.97%

cases:17.39%

controls:4.49%

—

250

440

193

497

659

—

Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]

1.5e+00

1.4e+00

—

cases:20.29%

controls:5.51%

cases:11.59%

controls:3.19%

—

652

668

—

propranolol; oral, parenteral
C07AA05 [21601670]

1.5e+00

1.3e+00

—

cases:17.39%

controls:4.64%

cases:10.14%

controls:2.90%

—

658

670

—

General Practice
1 [38004446]

1.4e+00

1.3e+00

—

cases:37.68%

controls:12.61%

cases:13.04%

controls:4.06%

—

603

662

—

Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]

1.4e+00

1.3e+00

—

cases:24.64%

controls:7.25%

cases:13.04%

controls:4.06%

—

640

662

—

Platelets [#/volume] in Blood
26515-7 [3007461]

6.6e-01

7.0e-01

1.4e+00

—

cases:52.17%

controls:36.09%

cases:43.48%

controls:27.68%

cases:15.94%

controls:4.35%

—

249

441

191

499

660

—

Eosinophils [#/volume] in Blood
26449-9 [3013115]

1.4e+00

1.3e+00

2.2e+00

—

cases:28.99%

controls:8.99%

cases:17.39%

controls:5.65%

cases:7.25%

controls:0.87%

—

628

651

684

—

25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]

1.4e+00

1.2e+00

—

cases:15.94%

controls:4.49%

cases:7.25%

controls:2.32%

—

659

674

—

Normoblasts [#/volume] in Blood
715-3 [3021589]

1.1e+00

1.4e+00

2.0e+00

—

cases:20.29%

controls:7.83%

cases:17.39%

controls:5.07%

cases:7.25%

controls:1.01%

—

636

655

683

—

Leukocytes [#/volume] in Blood
26464-8 [3010813]

6.4e-01

6.8e-01

1.4e+00

—

cases:52.17%

controls:36.52%

cases:43.48%

controls:27.97%

cases:15.94%

controls:4.64%

—

252

438

193

497

658

—

12 lead EKG panel
34534-8 [3044889]

1.3e+00

1.0e+00

—

cases:34.78%

controls:12.61%

cases:17.39%

controls:6.96%

—

603

642

—

Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]

1.2e+00

6.1e-01

—

cases:24.64%

controls:8.70%

cases:7.25%

controls:4.06%

—

630

662

—

Basophils [#/volume] in Blood
26444-0 [3006315]

1.2e+00

9.2e-01

—

cases:23.19%

controls:8.12%

cases:13.04%

controls:5.65%

—

634

651

—

Monocytes [#/volume] in Blood
26484-6 [3001604]

1.2e+00

9.2e-01

—

cases:23.19%

controls:8.12%

cases:13.04%

controls:5.65%

—

634

651

—

Lymphocytes [#/volume] in Blood
26474-7 [3019198]

1.2e+00

1.0e+00

—

cases:24.64%

controls:8.99%

cases:14.49%

controls:5.80%

—

628

650

—

Lymphocytes/Leukocytes in Blood
26478-8 [3002030]

1.2e+00

8.7e-01

—

cases:23.19%

controls:8.55%

cases:11.59%

controls:5.22%

—

631

654

—

Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]

1.2e+00

8.9e-01

-1.0e+50

—

cases:21.74%

controls:7.97%

cases:8.70%

controls:3.77%

cases:0.00%

controls:0.72%

—

635

664

685

—

Basophils/Leukocytes in Blood
30180-4 [3022096]

1.1e+00

9.0e-01

—

cases:21.74%

controls:8.12%

cases:11.59%

controls:5.07%

—

634

655

—

Monocytes/Leukocytes in Blood
26485-3 [3019069]

1.1e+00

8.7e-01

—

cases:21.74%

controls:8.26%

cases:11.59%

controls:5.22%

—

633

654

—

Eosinophils/Leukocytes in Blood
26450-7 [3006504]

1.1e+00

9.0e-01

—

cases:21.74%

controls:8.26%

cases:11.59%

controls:5.07%

—

633

655

—

Neutrophils/Leukocytes in Blood
26511-6 [3018010]

1.1e+00

9.6e-01

—

cases:23.19%

controls:8.99%

cases:11.59%

controls:4.78%

—

628

657

—

C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]

1.1e+00

6.6e-01

1.6e+00

—

cases:50.72%

controls:26.38%

cases:27.54%

controls:16.38%

cases:8.70%

controls:1.88%

—

182

508

113

577

677

—

Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]

1.0e+00

3.2e-01

—

cases:31.88%

controls:14.35%

cases:13.04%

controls:9.86%

—

591

622

—

Pharmacy visit
OMOP4822462 [581458]

-1.7e-01

3.0e-01

1.0e+00

-1.0e+50

—

cases:89.86%

controls:91.30%

cases:81.16%

controls:76.09%

cases:56.52%

controls:32.17%

cases:0.00%

controls:1.74%

—

630

525

165

222

468

678

—

Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]

9.7e-01

9.5e-01

1.5e+00

—

cases:37.68%

controls:18.70%

cases:28.99%

controls:13.62%

cases:8.70%

controls:2.03%

—

129

561

596

676

—

Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]

9.6e-01

7.6e-01

1.1e+00

—

cases:50.72%

controls:28.26%

cases:34.78%

controls:20.00%

cases:8.70%

controls:3.04%

—

195

495

138

552

669

—

CBC panel - Blood by Automated count
58410-2 [40761511]

8.6e-01

5.2e-01

1.0e+00

—

cases:49.28%

controls:29.13%

cases:27.54%

controls:18.41%

cases:7.25%

controls:2.75%

—

201

489

127

563

671

—

Kolposcopy
ULA02 [2001306679]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Acute appendicitis, unspecified
K35.9 [45557651]

-1.0e+50

—

cases:0.00%

controls:1.45%

—

680

—

Base excess in Venous blood by calculation
1927-3 [3002032]

—

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]

1.3e-01

-2.2e-01

—

cases:37.68%

controls:34.78%

cases:14.49%

controls:17.39%

—

240

450

120

570

—

prednisolone
S01BA04 [21603621]

-1.0e+50

—

cases:0.00%

controls:1.45%

—

680

—

triamcinolone and antiseptics
D07BB03 [21602150]

—

-1.0e+50

—

cases:0.00%

controls:1.30%

—

681

—

Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]

1.4e+00

—

cases:7.25%

controls:1.88%

—

677

—

ramipril; oral
C09AA05 [21601789]

-1.0e+50

—

cases:0.00%

controls:2.61%

cases:0.00%

controls:2.17%

cases:0.00%

controls:0.87%

—

672

675

684

—

Peritonsillar abscess
J36 [45581858]

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Surface analgesia on skin or mucosa
WX105 [2001310765]

—

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

betamethasone
C05AA05 [21601610]

4.9e-01

—

cases:8.70%

controls:5.51%

—

652

—

Embedded and impacted teeth
K01 [45533566]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Neurosurgery
14 [38004459]

—

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

miconazole
D01AC02 [21601921]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Gliadin peptide IgG Ab [Units/volume] in Serum by Immunoassay
63459-2 [40766189]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Migraine
G43 [45566873]

—

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Sytologyspecimen from mouth of uterus
XLD00 [2001306651]

-1.0e+50

—

cases:0.00%

controls:1.59%

—

679

—

tadalafil; oral
G04BE08 [21602653]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

fusidic acid
S01AA13 [21603564]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]

4.1e-01

—

-1.0e+50

—

cases:10.14%

controls:6.96%

—

cases:0.00%

controls:0.87%

—

642

—

684

—

valaciclovir; oral
J05AB11 [21603137]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

No disease
A97 [2002000230]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
X69 [45585661]

—

1.0e+50

—

cases:8.70%

controls:0.00%

—

690

—

lansoprazole; oral
A02BC03 [21600098]

—

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Obstetric epidural analgesia
WX307 [2001310797]

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

betamethasone
S03BA03 [21605203]

—

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Glucose tolerance 2 hours gestational panel - Serum or Plasma
81324-6 [21492888]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

amitriptyline; oral, parenteral
N06AA09 [21604696]

8.6e-01

—

cases:7.25%

controls:3.19%

—

668

—

diphenhydramine, combinations
R06AA52 [21603454]

-1.0e+50

—

cases:0.00%

controls:2.03%

—

676

—

codeine and paracetamol
N02AJ06 [1123647]

-5.5e-02

—

cases:11.59%

controls:12.17%

—

606

—

Chronic hypertension
205 [2001600203]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Dog dander IgE Ab [Units/volume] in Serum
6098-8 [3014133]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Ileoscopy through colon
UJF30 [2001305028]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Ear microscopy
UDC00 [2001301558]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Emergency Room and Inpatient Visit
ERIP [262]

—

1.7e+00

—

cases:7.25%

controls:1.45%

—

680

—

Cardiac arrhythmia, unspecified
I49.9 [45581778]

-1.0e+50

—

cases:0.00%

controls:1.45%

—

680

—

piroxicam; oral, parenteral, rectal
M01AC01 [21603961]

-1.0e+50

—

cases:0.00%

controls:4.20%

cases:0.00%

controls:1.59%

—

661

679

—

Primary gonarthrosis, bilateral
M17.0 [45562648]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

hydroxyethylpromethazine, combinations
R06AD55 [21603490]

-1.0e+50

—

cases:0.00%

controls:2.03%

—

676

—

metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]

—

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Ultrasound examination of pregnancy (at 12. week of gestaion or later) including basic examination of fetus
MA2AE [2001306829]

-1.0e+50

—

cases:0.00%

controls:3.04%

cases:0.00%

controls:0.72%

—

669

685

—

Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]

5.3e-01

—

-1.0e+50

—

cases:10.14%

controls:6.23%

—

cases:0.00%

controls:0.72%

—

647

—

685

—

Mental and behavioural disorders due to use of alcohol, Acute intoxication
F10.0 [45755372]

—

1.0e+50

—

cases:13.04%

controls:0.00%

—

690

—

brompheniramine, combinations
R06AB51 [21603466]

-1.0e+50

—

cases:0.00%

controls:2.46%

cases:0.00%

controls:0.87%

—

673

684

—

Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]

—

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

mometasone
D07AC13 [21602132]

-1.0e+50

—

cases:0.00%

controls:3.77%

cases:0.00%

controls:1.01%

—

664

683

—

omeprazole; oral, parenteral
A02BC01 [21600096]

8.6e-01

-1.0e+50

—

cases:7.25%

controls:3.19%

cases:0.00%

controls:1.30%

—

668

681

—

Toothache NOS
K08.80 [2000502799]

-1.0e+50

—

cases:0.00%

controls:1.30%

—

681

—

insulin (human); parenteral
A10AB01 [21600715]

—

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

adapalene, combinations; ointment
D10AD53 [21602299]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Diverticular disease of large intestine without perforation or abscess
K57.3 [45567316]

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Varicose veins of lower extremities without ulcer or inflammation
I83.9 [45552859]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

terbinafine; ointment
D01AE15 [21601954]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Neutrophil cytoplasmic Ab.classic [Titer] in Serum
32708-0 [3046294]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Rotator cuff syndrome
M75.1 [45596678]

-1.0e+50

—

cases:0.00%

controls:2.17%

—

675

—

Other chest pain
R07.3 [45597166]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

sildenafil; oral
G04BE03 [21602648]

—

1.9e+00

—

cases:7.25%

controls:1.16%

—

682

—

Streptococcus pyogenes [Presence] in Throat by Organism specific culture
11268-0 [3000924]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Diabetes mellitus arising in pregnancy
O24.4 [45543922]

-1.0e+50

—

cases:0.00%

controls:1.59%

cases:0.00%

controls:0.87%

—

679

684

—

Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]

6.2e-01

2.1e-01

—

cases:24.64%

controls:14.93%

cases:7.25%

controls:5.94%

—

103

587

649

—

Chronic tonsillitis
J35.0 [45548113]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Split tooth for reasons other than trauma
K03.82 [2000502700]

-1.0e+50

—

cases:0.00%

controls:0.87%

cases:0.00%

controls:1.01%

—

684

683

—

amoxicillin; oral, parenteral
J01CA04 [21602823]

-7.9e-02

—

cases:20.29%

controls:21.59%

—

149

541

—

Influenza virus A+B Ag [Presence] in Specimen
24015-0 [3024891]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Other single spontaneous delivery
O80.8 [45534307]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Acne
S96 [2002001060]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Thyrotropin receptor Ab [Units/volume] in Serum
5385-0 [3017044]

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

sulfadiazine and trimethoprim
J01EE02 [21602962]

—

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Pain/tenderness of skin
S01 [2002000966]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Estradiol (E2) [Moles/volume] in Serum or Plasma
14715-7 [3026725]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Foot/toe symptom/complaint
L17 [2002000641]

—

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Atrial fibrillation and flutter
I48 [45596206]

-1.0e+50

—

cases:0.00%

controls:1.45%

cases:0.00%

controls:0.72%

—

680

685

—

ketoprofen; ointment
M02AA10 [21604046]

-1.0e+50

—

cases:0.00%

controls:1.74%

—

678

—

naproxen; oral, rectal
M01AE02 [21603968]

-1.0e+50

—

cases:0.00%

controls:9.71%

—

623

—

hepatitis B, purified antigen
J07BC01 [21601338]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Atherosclerotic heart disease
I25.1 [45596196]

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Erythrocytes [#/volume] in Urine
30391-7 [3002582]

5.5e-01

—

cases:8.70%

controls:5.22%

—

654

—

Pharmacologic abortion
LCH11 [2001306623]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Neutrophil cytoplasmic Ab.perinuclear [Titer] in Serum
32787-4 [3043453]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Open wound of finger(s) without damage to nail
S61.0 [45578756]

-1.0e+50

—

cases:0.00%

controls:1.74%

—

678

—

indometacin; oral, parenteral, rectal
M01AB01 [21603941]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

zolpidem; oral
N05CF02 [21604655]

1.5e+00

—

cases:8.70%

controls:2.03%

—

676

—

Home Visit
OMOP4822459 [581476]

1.1e+00

—

cases:8.70%

controls:3.19%

—

668

—

Acute upper respiratory infection, unspecified
J06.9 [45562437]

—

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
3255-7 [3016407]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

hydrocortisone and antiseptics
D07BA04 [21602146]

—

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Diabetes insulin dependent
T89 [2002001130]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]

-1.0e+50

—

cases:0.00%

controls:2.17%

—

675

—

levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Procedure duration 120 to 149 minutes
ZXE15 [2001311406]

2.2e+00

—

cases:7.25%

controls:0.87%

—

684

—

Creatinine [Moles/volume] in Urine
14683-7 [3009508]

1.2e+00

—

-1.0e+50

—

cases:11.59%

controls:3.62%

—

cases:0.00%

controls:1.16%

—

665

—

682

—

Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]

7.1e-01

8.2e-01

-1.0e+50

—

cases:36.23%

controls:21.88%

cases:21.74%

controls:10.87%

cases:0.00%

controls:1.74%

—

151

539

615

678

—

montelukast; oral
R03DC03 [21603356]

—

-1.0e+50

—

cases:0.00%

controls:1.74%

—

678

—

Laparoscopic appendectomy
JEA01 [2001304803]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Telephone prescription or other care instructions
WZB00 [2001310884]

3.8e-01

—

cases:7.25%

controls:5.07%

—

655

—

Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]

7.3e-01

9.1e-01

-1.0e+50

—

cases:24.64%

controls:13.62%

cases:15.94%

controls:7.10%

cases:0.00%

controls:0.87%

—

596

641

684

—

Orthopedic Surgery
20 [38004465]

-9.2e-02

—

1.0e+50

—

cases:10.14%

controls:11.01%

—

cases:14.49%

controls:0.00%

—

614

—

690

—

budesonide; inhalant
R03BA02 [21603285]

—

-1.0e+50

—

cases:0.00%

controls:1.74%

—

678

—

Differential panel, method unspecified - Blood
69738-3 [42870588]

1.3e+00

9.3e-01

—

cases:14.49%

controls:4.35%

cases:8.70%

controls:3.62%

—

660

665

—

benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]

1.9e-01

—

cases:18.84%

controls:16.09%

—

111

579

—

Risk factor NOS
A23 [2002000158]

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Cat dander IgE Ab [Units/volume] in Serum
6833-8 [3023430]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

boric acid
S02AA03 [21605149]

-1.0e+50

—

cases:0.00%

controls:1.45%

—

680

—

cyproterone and estrogen
G03HB01 [21602617]

-1.0e+50

—

cases:0.00%

controls:1.59%

—

679

—

Type 1 diabetes mellitus
E10 [45576436]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

chlorhexidine
S02AA09 [21605155]

—

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Health check-up performed during second study year in students of upper secondary schools, vocational schools etc.
SPAT1364 [2001700465]

-1.0e+50

—

cases:0.00%

controls:2.32%

cases:0.00%

controls:1.01%

—

674

683

—

Person consulting for explanation of investigation findings
Z71.2 [45552100]

—

-1.0e+50

—

cases:0.00%

controls:1.59%

—

679

—

Systematic individual therapy, cognitive-behavioural
IDY03 [2001304164]

—

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

sulfasalazine; oral, rectal
A07EC01 [21600663]

-1.0e+50

—

cases:0.00%

controls:1.16%

cases:0.00%

controls:0.72%

—

682

685

—

C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method
30522-7 [3010156]

—

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

dextromethorphan; oral
R05DA09 [21603404]

-1.0e+50

—

cases:0.00%

controls:2.32%

—

674

—

IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]

-1.0e+50

—

cases:0.00%

controls:1.30%

cases:0.00%

controls:0.87%

—

681

684

—

piroxicam; ointment
M02AA07 [21604043]

-1.0e+50

—

cases:0.00%

controls:3.77%

cases:0.00%

controls:1.30%

—

664

681

—

Extensive health certificate
SPAT1284 [2001700385]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Examination for adolescent development state
Z00.3 [45580999]

-1.0e+50

—

cases:0.00%

controls:1.74%

—

678

—

mesalazine; oral, rectal
A07EC02 [21600664]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Complicated extraction of tooth
EBA05 [2001301924]

—

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Physiotherapy
R4110 [2001310233]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

chlorhexidine
D09AA12 [21602275]

—

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Intramuscular and subcutaneous injection
SPAT1256 [2001700357]

-1.0e-01

—

cases:7.25%

controls:7.97%

—

635

—

Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

alfuzosin; oral
G04CA01 [21602668]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Special examination of mouth
SAA04 [2001310277]

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Shigella sp [Presence] in Stool by Culture
82300-5 [42529406]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

erdosteine; oral
R05CB15 [21603394]

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Campylobacter sp identified in Tissue by Organism specific culture
20740-7 [3006418]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Intraoral radiographic dental examination
EB1AA [2001301903]

5.4e-01

6.5e-01

-1.0e+50

—

cases:18.84%

controls:11.88%

cases:7.25%

controls:3.91%

cases:0.00%

controls:1.01%

—

608

663

683

—

tramadol; oral, parenteral, rectal
N02AX02 [21604298]

2.4e-01

—

cases:7.25%

controls:5.80%

—

650

—

Sinus symptom/complaint
R09 [2002000890]

-1.0e+50

—

cases:0.00%

controls:1.30%

—

681

—

Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
18500-9 [3018006]

—

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Dental examination
Z01.2 [45581002]

7.4e-01

—

cases:17.39%

controls:9.13%

—

627

—

chlorhexidine
S03AA04 [21605193]

—

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

SMOKING - SMOKE2: no - SMOKE3: Unspecified - SMOKE5: Unspecified
SMOKING-2-0-0 [2002330112]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Ambulatory ECG
XF404 [2001303370]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Calculus of gallbladder without cholecystitis
K80.2 [45552951]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

folic acid; oral, parenteral
B03BB01 [21601129]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

False labour before 37 completed weeks of gestation
O47.0 [45582556]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Assistance to normal delivery
MAX99 [2001306918]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Three-surface restoration
SFA30 [2001310360]

1.0e+00

—

cases:13.04%

controls:5.22%

—

654

—

prednisolone
A07EA01 [21600653]

-1.8e-02

—

cases:8.70%

controls:8.84%

—

629

—

Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

escitalopram; oral
N06AB10 [21604718]

7.0e-01

1.6e+00

—

cases:8.70%

controls:4.49%

cases:10.14%

controls:2.32%

—

659

674

—

Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum
31374-2 [3007080]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Social worker
Z2446 [2001311559]

1.6e+00

—

cases:8.70%

controls:1.88%

—

677

—

Examination and observation for other specified reasons
Z04.8 [45552063]

—

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Maternal care due to uterine scar from previous surgery
O34.2 [45572805]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Supervision of normal first pregnancy
Z34.0 [45595500]

-1.0e+50

—

cases:0.00%

controls:1.30%

—

681

—

Cough
R05 [45606792]

—

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

pseudoephedrine; oral
R01BA02 [21603210]

—

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Ultrasound examination of upper part of abdomen
JN1AE [2001305517]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]

1.1e+00

—

cases:7.25%

controls:2.61%

—

672

—

Abdominal pain/cramps general
D01 [2002000300]

1.3e+00

-1.0e+50

—

cases:7.25%

controls:2.03%

cases:0.00%

controls:0.87%

—

676

684

—

Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Hemolysis interference index of Serum or Plasma
46424-8 [3052851]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

insulin lispro; parenteral
A10AC04 [21600726]

-1.0e+50

—

cases:0.00%

controls:1.74%

cases:0.00%

controls:1.59%

—

678

679

—

Detailed morfological ultrasound examination of fetus
MA2HE [2001306836]

-1.0e+50

—

cases:0.00%

controls:2.17%

cases:0.00%

controls:0.72%

—

675

685

—

estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]

—

-1.0e+50

—

cases:0.00%

controls:2.32%

—

674

—

opium derivatives and expectorants
R05FA02 [21603439]

-1.0e+50

—

cases:0.00%

controls:2.03%

—

676

—

Routine postpartum follow-up
Z39.2 [45547306]

-1.0e+50

—

cases:0.00%

controls:2.03%

cases:0.00%

controls:1.16%

—

676

682

—

Provision of consultation response
SPAT1285 [2001700386]

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Planned health check-up monitoring, health check-up performed based on individual need
SPAT1317 [2001700418]

—

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

Recurrent depression, severe episode without somatic syndrome
F33.30 [2000501986]

—

1.0e+50

—

cases:7.25%

controls:0.00%

—

690

—

Health examination of person liable for military service
SPAT1321 [2001700422]

—

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Diabetes non-insulin dependent
T90 [2002001131]

—

-1.0e+50

—

cases:0.00%

controls:1.59%

—

679

—

salbutamol; inhalant
R03AC02 [21603256]

-6.9e-02

—

cases:11.59%

controls:12.32%

—

605

—

Outcome of delivery
Z37 [45581024]

-1.0e+50

—

cases:0.00%

controls:5.36%

cases:0.00%

controls:1.74%

—

653

678

—

Bloodpressure measurement
XF600 [2001303376]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

clindamycin
D10AF01 [21602305]

-1.0e+50

—

cases:0.00%

controls:1.30%

—

681

—

lisinopril; oral
C09AA03 [21601787]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Migraine without aura [common migraine]
G43.0 [45600784]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]

—

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

Obstetrics / Gynecology
16 [38004461]

-7.9e-01

—

cases:7.25%

controls:14.64%

—

101

589

—

betamethasone
S02BA07 [21605169]

4.9e-01

—

cases:8.70%

controls:5.51%

—

652

—

Cervicobrachial syndrome
M53.1 [45567577]

-1.0e+50

—

cases:0.00%

controls:1.16%

—

682

—

diclofenac; ointment
M02AA15 [21604051]

—

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

hydrocortisone butyrate
D07AB02 [21602106]

7.5e-01

—

cases:10.14%

controls:5.07%

—

655

—

Dental calculus supragingival
K03.64 [2000502689]

7.6e-01

—

cases:13.04%

controls:6.52%

—

645

—

Syncope and collapse
R55 [45568141]

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]

-1.0e+50

—

cases:0.00%

controls:1.30%

—

681

—

Midwife
Z3232 [2001311563]

-1.0e+50

—

cases:0.00%

controls:1.30%

—

681

—

Albumin [Mass/volume] in Urine
1754-1 [3012516]

—

-1.0e+50

—

cases:0.00%

controls:2.32%

cases:0.00%

controls:1.01%

—

674

683

—

Removal of sutures
SPAT1153 [2001700254]

-1.0e+50

—

cases:0.00%

controls:3.04%

—

669

—

Neutrophils [#/volume] in Blood
26499-4 [3017732]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

General examination of pregnant woman
XMA22 [2001306916]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Acute cystitis
N30.0 [45601724]

-1.0e+50

—

cases:0.00%

controls:1.30%

—

681

—

Essential (primary) hypertension
I10 [45591453]

5.5e-01

—

cases:8.70%

controls:5.22%

—

654

—

FEV1 --post bronchodilation
20155-8 [3023550]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

hydrocortisone
D07AA02 [21602102]

7.5e-01

—

cases:10.14%

controls:5.07%

—

655

—

Extraction of tooth
EBA00 [2001301923]

1.6e-01

-1.0e+50

—

cases:7.25%

controls:6.23%

cases:0.00%

controls:1.74%

—

647

678

—

Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]

—

-1.0e+50

—

cases:0.00%

controls:0.87%

—

684

—

sitagliptin; oral
A10BH01 [21600784]

-1.0e+50

—

cases:0.00%

controls:0.72%

cases:0.00%

controls:0.72%

—

685

—

cefuroxime; oral, parenteral
J01DC02 [21602884]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

carbamazepine; oral, rectal
N03AF01 [21604417]

-1.0e+50

—

cases:0.00%

controls:1.01%

—

683

—

Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]

5.8e-01

—

cases:7.25%

controls:4.20%

—

661

—

Iron deficiency anaemia
B80 [2002000291]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

levocetirizine; oral
R06AE09 [21603498]

—

-1.0e+50

—

cases:0.00%

controls:1.30%

—

681

—

Emergency visit or other similar visit involving procedures
WYA05 [2001310871]

1.3e-01

—

cases:11.59%

controls:10.29%

—

619

—

Thyrotoxicosis, unspecified
E05.9 [45586131]

-1.0e+50

—

cases:0.00%

controls:0.72%

—

685

—

Extensive health check-up of expecting family
SPAT1197 [2001700298]

-1.0e+50

—

cases:0.00%

controls:2.46%

cases:0.00%

controls:0.72%

—

673

685

—

short-acting sulfonamides - combinations
J01EB20 [21602943]

-1.0e+50

—

cases:0.00%

controls:2.03%

—

676

—

Small restoration
SFA00 [2001310357]

-1.0e+50

—

cases:0.00%

controls:1.45%

—

680

—

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3028707) Methadone [Presence] in Urine by Screen method

10.17

9.09

4.5

1.7

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

5.86

8.75

4.5

1.4

—

(3008832) Norclozapine [Moles/volume] in Serum or Plasma

17.79

8.05

23.9

9.6

765.25

912.75

nmol/l

—

(3000081) cloZAPine [Moles/volume] in Serum or Plasma

17.79

8.05

38.7

12.4

1258.92

1432.88

nmol/l

—

(3011288) Drugs identified in Urine by Screen method Nominal

5.04

6.82

6.4

1.6

—

(3016879) Cocaine [Presence] in Urine

4.57

6.59

4.3

1.4

—

(3027008) Opiates [Presence] in Urine

4.22

5.96

4.3

1.4

—

(3028300) Cannabinoids [Presence] in Urine

4.22

5.96

4.4

1.4

—

(3027944) Amphetamines [Presence] in Urine

4.06

5.68

4.4

1.4

—

(3000764) Benzodiazepines [Presence] in Urine

4.06

5.68

4.3

1.4

—

(3010813) Leukocytes [#/volume] in Blood

650

0.22

5.43

46.7

17.8

7.15

6.61

e9/l

1.27

641

(3007461) Platelets [#/volume] in Blood

648

0.23

5.09

46.2

17.8

251.87

251.10

e9/l

0.02

640

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

483

0.33

4.87

3.5

3.9

—

(3019309) Folate [Moles/volume] in Red Blood Cells

3.77

4.75

1.8

1.6

862.18

1315.86

nmol/l

0.96

(1761868) Lipid panel - Serum or Plasma

304

0.29

4.06

3.6

2.7

—

(3026361) Erythrocytes [#/volume] in Blood

650

0.24

3.89

45.4

17.7

4.59

4.70

e12/l

0.65

641

(42870588) Differential panel, method unspecified - Blood

155

2.50

3.28

9.6

7.3

—

(42868678) Cholesterol non HDL [Moles/volume] in Serum or Plasma

0.00

2.98

0.0

2.0

—

3.46

—

(3020779) Urea [Moles/volume] in Serum or Plasma

3.59

2.64

12.8

13.4

7.68

6.61

mmol/l

—

(3000492) Spirometry study

0.00

2.59

0.0

1.3

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

2.95

2.51

2.8

—

(40758558) Short blood count panel - Blood

148

2.21

2.44

17.7

5.7

—

(3024666) Lithium [Moles/volume] in Serum or Plasma

6.63

2.41

17.2

10.1

0.54

mmol/l

—

(3019150) Specific gravity of Urine by Refractometry

127

2.22

2.31

3.2

2.7

1.01

1.02

kg/l

0.49

(3014218) Bicarbonate [Moles/volume] standard in Arterial blood

3.77

2.11

3.0

21.4

24.29

24.33

mmol/l

—

(3015235) Bicarbonate [Moles/volume] in Capillary blood

4.27

2.08

4.5

1.3

26.68

24.22

mmol/l

—

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

0.00

1.77

0.0

1.5

—

859.09

—

(40768804) Tissue Pathology biopsy report

193

0.44

1.63

1.7

—

(3020891) Body temperature

3.51

1.55

11.2

3.6

37.14

36.98

°c

—

(3019060) Gas panel - Arterial blood

3.28

1.46

10.6

34.9

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

2.57

1.43

3.6

11.4

22.74

24.51

mmol/l

—

(3017181) Myelocytes/Leukocytes in Blood

2.32

1.41

17.7

5.1

3.60

0.53

—

(3008898) HLA-B27 [Presence]

0.00

1.39

0.0

1.1

—

(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma

2.13

1.37

2.4

3.4

4.57

10.34

umol/l

—

(40761535) Cells panel - Urine sediment

2.64

1.33

4.0

2.8

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

2.64

1.33

1.7

1.5

—

(40761511) CBC panel - Blood by Automated count

603

0.52

1.28

20.6

10.1

—

(3003694) ABO and Rh group [Type] in Blood

177

0.49

1.25

1.5

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

1.94

1.24

1.6

1.7

372.00

509.93

pmol/l

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

181

1.70

1.24

2.1

1.8

89.68

97.68

pmol/l

0.39

(3004529) Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood

2.75

1.24

7.4

3.0

51.04

45.66

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

2.17

1.23

7.4

10.8

104.90

104.82

mmol/l

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

2.43

1.21

3.5

1.1

—

(4035726) Immunohistochemistry procedure

0.00

1.20

0.0

1.5

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

0.00

1.20

0.0

1.7

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

181

0.53

1.08

1.8

1.7

—

(3000991) Gas panel - Venous blood

2.11

1.03

6.1

13.7

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

0.00

1.00

0.0

1.3

—

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

0.00

1.00

0.0

1.3

—

1.08

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

0.00

1.00

0.0

1.3

—

0.91

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

0.00

1.00

0.0

1.3

—

0.96

—

(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma

0.00

0.99

0.0

1.6

—

47.33

—

(3050129) First trimester maternal screen panel - Serum or Plasma

0.00

0.98

0.0

1.3

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

231

0.60

0.96

3.1

2.9

—

estimate

—

(3035350) Ketones [Presence] in Urine by Test strip

294

0.63

0.96

2.5

3.0

0.00

estimate

—

(3009261) Glucose [Presence] in Urine by Test strip

294

0.63

0.96

2.5

3.1

0.00

estimate

—

(3023368) Bacteria identified in Blood by Culture

114

1.65

0.90

3.1

4.8

—

(3021601) Nitrite [Presence] in Urine by Test strip

289

0.65

0.86

2.5

3.0

0.00

estimate

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

1.96

0.84

8.0

3.8

—

(3017895) Helicobacter pylori Ab [Units/volume] in Serum

0.00

0.81

0.0

1.7

—

8.31

—

(3005033) Fetal Nuchal fold Thickness US

0.00

0.80

0.0

1.2

—

1.34

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

0.00

0.80

0.0

1.2

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

0.79

0.0

1.4

—

(3021960) Folate [Moles/volume] in Serum or Plasma

110

1.59

0.77

1.6

1.5

22.33

18.82

nmol/l

0.77

100

(3026008) Bacteria identified in Urine by Culture

119

1.57

0.76

1.9

2.5

—

(3019832) Treponema pallidum Ab [Presence] in Serum

120

0.54

0.76

1.7

2.1

—

(3009508) Creatinine [Moles/volume] in Urine

164

1.50

0.75

5.8

3.3

5.79

9.69

mmol/l

3.45

148

(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction

1.79

0.72

2.9

3.0

260.86

250.00

u/l

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

235

0.68

0.64

2.7

2.8

0.00

0.02

estimate

—

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

1.72

0.62

1.6

1.3

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

0.61

0.0

1.5

—

(3034770) Mitochondria Ab [Titer] in Serum

0.00

0.61

0.0

1.3

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

0.61

0.0

1.4

—

(3037551) Cancer Ag 125 [Units/volume] in Serum or Plasma

0.00

0.61

0.0

1.4

—

31.44

—

(3013512) EKG study

125

1.48

0.61

3.7

2.9

—

(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum

0.00

0.59

0.0

1.3

—

(3044889) 12 lead EKG panel

356

1.37

0.58

4.4

3.0

—

(3004248) Sex hormone binding globulin [Moles/volume] in Serum or Plasma

1.51

0.48

3.4

1.8

36.86

36.38

nmol/l

—

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

1.53

0.47

1.5

2.1

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

1.46

0.44

1.5

1.6

—

(3009041) Cardiolipin IgG Ab [Units/volume] in Serum by Immunoassay

0.00

0.42

0.0

1.1

—

6.25

—

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

0.00

0.42

0.0

1.5

—

(3002385) Erythrocyte [DistWidth] in Red Blood Cells

509

0.76

0.41

38.9

14.4

13.58

13.23

1.10

504

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.41

0.0

1.9

—

(4024509) Urine culture

0.00

0.40

0.0

1.6

—

(3002523) Influenza virus A Ag [Presence] in Specimen

0.00

0.39

0.0

1.2

—

(3019250) Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay

0.00

0.39

0.0

2.6

—

173.26

—

(3003740) Influenza virus B Ag [Presence] in Specimen

0.00

0.39

0.0

1.2

—

(3011960) Natriuretic peptide B [Mass/volume] in Serum or Plasma

0.00

0.39

0.0

6.2

—

91.11

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

1.42

0.39

1.2

1.6

—

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

1.37

0.32

1.6

2.2

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.33

0.31

1.6

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

112

1.31

0.31

1.9

1.7

—

(3007853) Bacteria identified in Skin by Aerobe culture

1.30

0.29

1.4

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

1.21

0.26

2.2

1.7

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

0.72

0.24

1.3

1.6

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

164

1.22

0.23

2.7

2.8

75.62

14.49

ng/l

0.52

(3029937) Albumin [Presence] in Urine by Test strip

146

1.22

0.22

2.6

3.0

0.00

estimate

—

(3020044) Glucose [Moles/volume] in Cerebral spinal fluid

0.00

0.21

0.0

1.1

—

3.75

—

(40766183) Gliadin peptide IgA Ab [Units/volume] in Serum by Immunoassay

0.00

0.21

0.0

1.1

—

1.50

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

0.00

0.21

0.0

1.1

—

(3019897) Erythrocyte [DistWidth] in Red Blood Cells by Automated count

0.00

0.21

0.0

1.3

—

13.09

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

1.5

—

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

1.4

—

(3034274) Bile acid [Moles/volume] in Serum --fasting

0.00

0.21

0.0

1.7

—

2.84

—

(21492711) Cytomegalovirus IgG Ab avidity [Presence] in Serum or Plasma by Immunoassay

0.00

0.21

0.0

1.2

—

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

1.3

—

(3042596) Human coronavirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

1.3

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

0.00

0.21

0.0

1.2

—

(3044290) Cell count panel - Cerebral spinal fluid

0.00

0.21

0.0

1.1

—

(3019473) Protein [Mass/volume] in Cerebral spinal fluid

0.00

0.21

0.0

1.2

—

464.00

—

(3015916) Alpha-1-Fetoprotein [Units/volume] in Serum or Plasma

0.00

0.21

0.0

2.5

—

10.78

—

(3047007) Chlamydophila sp Ab [Presence] in Serum

0.00

0.21

0.0

1.1

—

(3024980) IgG subclass 4 [Mass/volume] in Serum

0.00

0.21

0.0

1.5

—

0.48

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

572

0.81

0.21

18.4

12.1

19.09

23.02

mg/l

0.65

451

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

0.00

0.21

0.0

1.0

—

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

1.2

—

(3012220) Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay

0.00

0.21

0.0

1.1

—

(3019539) Treponema pallidum Ab [Titer] in Serum by Hemagglutination

0.00

0.21

0.0

1.5

—

(3038177) Helicobacter pylori Ab [Presence] in Serum

0.00

0.21

0.0

1.1

—

(3003265) Liver kidney microsomal Ab [Titer] in Serum by Immunofluorescence

0.00

0.21

0.0

1.2

—

(3014148) Varicella zoster virus Ab [Titer] in Serum

0.00

0.21

0.0

1.2

—

(3029634) Reagin Ab [Titer] in Serum by VDRL

0.00

0.20

0.0

1.4

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

0.00

0.20

0.0

1.5

—

39.88

—

(3026725) Estradiol (E2) [Moles/volume] in Serum or Plasma

0.00

0.20

0.0

1.5

—

0.21

—

(40768793) Breast Pathology biopsy report

0.00

0.20

0.0

1.4

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.20

0.0

1.5

—

(40761536) Microorganisms panel - Urine sediment

1.17

0.19

2.3

2.6

—

(3023103) Potassium [Moles/volume] in Serum or Plasma

558

0.85

0.14

20.1

13.3

3.91

3.93

mmol/l

0.31

550

(3015736) pH of Urine

230

1.14

0.14

3.2

2.7

6.46

6.11

0.46

137

(3044640) Blood type and Crossmatch panel - Blood

158

0.86

0.14

3.1

2.1

—

(40760892) CBC W Ordered Manual Differential panel - Blood

153

1.15

0.12

15.1

5.2

—

(3019550) Sodium [Moles/volume] in Serum or Plasma

556

0.87

0.12

21.6

13.1

139.83

139.77

mmol/l

0.09

550

(46235355) HIV 1 and 2 tests - Meaningful Use set

204

1.12

0.10

2.2

2.3

—

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

126

1.14

0.10

1.4

1.7

1.46

1.24

mg/l

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

153

0.89

0.08

2.5

1.7

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

153

0.89

0.08

2.2

2.6

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

1.06

0.08

1.6

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

143

0.97

0.00

2.0

2.5

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

115

1.05

0.00

2.8

2.2

—

(36304419) Bacteria [Presence] in Urine

149

1.01

0.00

1.5

2.2

—

estimate

—

(3012413) Glucose [Moles/volume] in Serum or Plasma --2 hours post meal

0.00

0.0

1.2

—

7.26

—

(3000855) Microscopic observation [Identifier] in Vaginal fluid by Gram stain

0.00

0.0

1.5

—

(3021236) Streptolysin O Ab [Units/volume] in Serum or Plasma

0.00

0.0

1.0

—

142.76

—

(3001788) Aldosterone [Moles/volume] in Serum or Plasma

0.00

0.0

1.3

—

254.12

—

(40766800) Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] corrected for background in Blood

0.00

0.0

1.6

—

(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing

0.00

0.0

1.8

—

(3005757) Coagulation factor V activity actual/normal in Platelet poor plasma by Coagulation assay

0.00

0.0

2.0

—

110.50

—

(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.3

—

(3028369) Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.3

—

(40758310) Human epididymis protein 4 [Moles/volume] in Serum or Plasma

0.00

0.0

1.1

—

47.89

—

(3050238) Crystals [Presence] in Synovial fluid by Light microscopy

0.00

0.0

1.4

—

(3042206) Streptococcus agalactiae Ag [Presence] in Vaginal fluid

0.00

0.0

1.1

—

(3011985) Renin [Units/volume] in Plasma

0.00

0.0

1.2

—

20.29

—

(3014702) Chromogranin A [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

5.2

—

1.30

—

(3018333) Ribosomal P Ab [Presence] in Serum

0.00

-0.00

0.0

1.4

—

(3041354) Potassium [Moles/volume] in Venous blood

0.00

-0.00

0.0

1.4

—

3.96

—

(3026179) Normetanephrine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

0.44

—

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.3

—

(44790048) Parainfluenza type 2 nucleic acid detection

0.00

-0.00

0.0

1.4

—

(3019601) Blood group antibody investigation [Interpretation] in Plasma or RBC

0.00

-0.00

0.0

1.2

—

(40761995) Spermatozoa Progressive [#/volume] in Semen

0.00

-0.00

0.0

2.6

—

43.20

—

(3005570) Glucose [Moles/volume] in Urine

0.00

-0.00

0.0

1.0

—

(40759812) SCL-70 extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.5

—

(4062490) Immunoglobulin typing, IgG

0.00

-0.00

0.0

1.0

—

(3010380) Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid

0.00

-0.00

0.0

1.0

—

(44806118) Parainfluenza type 4 nucleic acid detection

0.00

-0.00

0.0

1.4

—

(3037756) Immunofixation for Serum or Plasma

0.00

-0.00

0.0

3.1

—

(21494815) CD4 cells/Lymphocytes in Specimen

0.00

-0.00

0.0

2.4

—

47.33

—

(3023410) Appearance of Cerebral spinal fluid

0.00

-0.00

0.0

1.2

—

(3011166) Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid

0.00

-0.00

0.0

1.0

—

(3014973) Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid

0.00

-0.00

0.0

1.0

—

(3044941) Cell count panel - Synovial fluid

0.00

-0.00

0.0

1.0

—

(3025018) Bordetella pertussis Ab [Titer] in Serum

0.00

-0.00

0.0

1.2

—

(44790049) Parainfluenza type 3 nucleic acid detection

0.00

-0.00

0.0

1.4

—

(3015183) Erythrocyte sedimentation rate [Velocity] in Red Blood Cells

0.00

-0.00

0.0

1.6

—

16.29

—

(40764126) Parainfluenza virus RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.3

—

(3035285) Chloride [Moles/volume] in Venous blood

0.00

-0.00

0.0

1.4

—

109.60

—

(40759842) Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.4

—

(3016018) Differential panel - Cerebral spinal fluid

0.00

-0.00

0.0

1.0

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

-0.00

0.0

2.4

—

18.60

—

(1175426) CD3 cells/Lymphocytes in Blood

0.00

-0.00

0.0

1.6

—

86.40

—

(3027135) IgG subclass 1 [Mass/volume] in Serum

0.00

-0.00

0.0

1.0

—

5.93

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

1.00

-0.00

2.2

1.8

—

(43055089) Myosin Ab [Presence] in Serum or Plasma by Immunoblot

0.00

-0.00

0.0

1.0

—

(40768441) Liver Pathology biopsy report

0.00

-0.00

0.0

1.3

—

(3033705) Calcium.ionized [Moles/volume] in Venous blood

0.00

-0.00

0.0

1.4

—

1.18

—

(3003181) Sodium [Moles/volume] in Urine

0.00

-0.00

0.0

1.0

—

86.00

—

(40759836) Histone Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.6

—

(3046294) Neutrophil cytoplasmic Ab.classic [Titer] in Serum

0.00

-0.00

0.0

1.0

—

(40759843) Sjogrens syndrome-A extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.6

—

(3009595) Pneumocystis jirovecii DNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.6

—

(3042975) Streptococcus sp identified in Isolate by Organism specific culture

0.00

-0.00

0.0

1.0

—

(40759844) Sjogrens syndrome-B extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.6

—

(3027831) CD3-CD16+CD56+ (Natural killer) cells/cells in Blood

0.00

-0.00

0.0

1.6

—

7.40

—

(3020717) Zinc [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.3

—

12.73

—

(3024474) Albumin [Mass/volume] in Cerebral spinal fluid

0.00

-0.00

0.0

1.0

—

262.60

—

(3024139) IgG subclass 3 [Mass/volume] in Serum

0.00

-0.00

0.0

1.0

—

0.41

—

(3023419) Bacteria identified in Sputum by Culture

0.00

-0.00

0.0

2.6

—

(40759850) Jo-1 extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.6

—

(40762119) U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum

0.00

-0.00

0.0

1.7

—

(3022689) Creatine [Moles/volume] in Urine

0.00

-0.00

0.0

1.0

—

8.62

—

(3035320) C reactive protein [Mass/volume] in Body fluid

0.00

-0.00

0.0

1.8

—

22.00

—

(3014043) Spermatozoa Nonprogressive/Spermatozoa in Semen

0.00

-0.00

0.0

5.2

—

8.40

—

(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight

0.00

-0.00

0.0

1.2

—

(4133840) Spirometry

0.00

-0.00

0.0

1.0

—

(3028192) IgG subclass 2 [Mass/volume] in Serum

0.00

-0.00

0.0

1.0

—

2.16

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

-0.00

0.0

4.4

—

16.50

—

(3000034) Microalbumin [Mass/volume] in Urine

0.00

-0.00

0.0

3.0

—

21.50

—

(40759849) Smith extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.6

—

(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay

0.00

-0.00

0.0

3.2

—

97.80

—

(3028167) CD3+CD4+ (T4 helper) cells [#/volume] in Blood

0.00

-0.00

0.0

1.4

—

0.48

—

(44790047) Parainfluenza type 1 nucleic acid detection

0.00

-0.00

0.0

1.4

—

(3042936) Bacteria identified in Isolate by Culture

1.00

-0.00

3.0

2.6

—

(3038515) Glucose [Moles/volume] in Venous blood

0.00

-0.00

0.0

2.1

—

5.69

—

(3035637) Corticotropin [Mass/volume] in Plasma

0.00

-0.00

0.0

1.7

—

21.29

—

(3030408) 3-Methoxytyramine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

(40765089) Chromosome analysis panel - Blood by G-banded

0.00

-0.00

0.0

1.0

—

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: VWXY20_INTENTI_SELF_H_JUMPI_LYING_MOVING_OBJECT – Intentional self-harm by jumping or lying before moving object

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

≡ Risteys

R14

FinnGen R13 + FinRegistry

FinnGen R12 + FinRegistry

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Intentional self-harm by jumping or lying before moving object

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

All original rules

Similar endpoints

Case counts by codes

Upset plot

Case counts by code for Intentional self-harm by jumping or lying before moving object (VWXY20_INTENTI_SELF_H_JUMPI_LYING_MOVING_OBJECT)

Summary Statistics

-FinRegistry-

-FinnGen-

Key figures

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

TimeCodeWAS

LabWAS

Mortality – FinRegistry

Relationships between endpoints